Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cirmtuzumab||UC-961||Cirmtuzumab (UC-961) is a monoclonal antibody that binds to human receptor tyrosine kinase-like orphan receptor 1 (ROR1) and blocks ROR1 signaling, leading to growth inhibition in tumor cells (PMID: 26297272, PMID: 29859176, PMID: 32090643).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||chronic lymphocytic leukemia||not applicable||Cirmtuzumab||Phase I||Actionable||In a Phase I trial, treatment with Cirmtuzumab (UC-961) was safe and well-tolerated and resulted in stable disease in 77% (17/22) of chronic lymphocytic leukemia patients, and a median time to next treatment of 8.6 months (PMID: 29859176).||29859176|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02222688||Phase I||Cirmtuzumab||UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia||Completed|
|NCT03088878||Phase Ib/II||Cirmtuzumab Cirmtuzumab + Ibrutinib Ibrutinib||A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies||Recruiting|
|NCT02860676||Phase I||Cirmtuzumab||Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961||Completed|